With the health care stakeholder landscape evolving to place much more emphasis on the value that a drug brings to both patients and payers, biopharma companies need to adapt their approach to portfolio planning. Companies need to align their investment to products that will bring the greatest value to customers, to maximise their chance of commercial success. This white paper, authored by members of Quintiles’ Consulting team in Europe, outlines the necessary evolution of Portfolio Management to respond to growing demands of stakeholders, in particular, payers expecting that value be demonstrated and better inform decision-making.